| Popis: |
The introduction of the phosphodiesterase type 5 inhibitors (PDE inhibitors) has been a major step forward in the treatment of erectile dysfunction (ED). Though efficacious and safe, 50% of men discontinue treatment, largely because other sexological issues have not been properly addressed. To predict onset and duration of action, insight into the pharmacokinetics of the PDE inhibitors is required. In men whose testosterone levels are low, testosterone substitution may booster the efficacy of PDE inhibitors. Before receiving PDE inhibitor the cardiovascular status of a patient must be assessed. The main action of testosterone is on the central nervous system. It improves libido and mood. Levels in the low-normal range suffice. |
